Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and safety study of GSK Biologicals' meningococcal vaccine GSK134612 administered in healthy subjects either previously primed with Mencevax ACWY [meningococcal vaccine groups A C Y W-135 polysaccharide] or naive to meningococcal vaccination.

Trial Profile

Immunogenicity and safety study of GSK Biologicals' meningococcal vaccine GSK134612 administered in healthy subjects either previously primed with Mencevax ACWY [meningococcal vaccine groups A C Y W-135 polysaccharide] or naive to meningococcal vaccination.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Feb 2009 Actual patient numbers (272) added as reported by ClinicalTrials.gov.
    • 02 Feb 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 02 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top